Nancy Wysenski
CIK 1294596 · EVP, Chief Commercial Officer · last filed 2026-05-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$18.19M
Companies
9
Total Filings
83
Lifetime Open-Market Net
-$34.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYTK | Director | 33,917 | $70.15 | $2.38M | $0 | 29 | 2026-05-27 |
| ALKS | Director | 33,028 | $44.28 | $1.46M | -$1.01M | 19 | 2023-07-10 |
| Provention Bio, Inc. (PRVB) Delisted | Director | — | $24.98 | — | $0 | 5 | 2023-04-27 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $0 | 4 | 2019-11-12 |
| TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted | Director | — | — | — | $0 | 6 | 2019-06-11 |
| INO | Director | 5,000 | $1.10 | $5.5K | $0 | 4 | 2016-05-16 |
| VRTX | EVP, Chief Commercial Officer | 32,232 | $444.93 | $14.34M | -$33.93M | 11 | 2012-06-01 |
| ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted | Chief Operating Officer | 13,054 | $0.29 | $3.8K | $0 | 3 | 2009-03-02 |
| NORTH AMERICAN SCIENTIFIC INC (NASI) Delisted | Director | — | — | — | $0 | 2 | 2008-05-01 |
Recent Filings · Page 3 of 9
83 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-04 | CYTK | Grant (A) | +126 | $5.6K | EDGAR |
| 2022-10-05 | CYTK | Grant (A) | +110 | $5.6K | EDGAR |
| 2022-07-12 | CYTK | Grant (A) | +137 | $5.6K | EDGAR |
| 2022-07-08 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2022-06-16 | ALKS | Mixed | +6,890 | -$18.9K | EDGAR |
| 2022-05-18 | Provention Bio, Inc. (PRVB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-11 | CYTK | Grant (A) | +5,000 | $0 | EDGAR |
| 2022-04-01 | CYTK | Grant (A) | +146 | $5.6K | EDGAR |
| 2022-01-04 | CYTK | Grant (A) | +122 | $5.6K | EDGAR |
| 2021-12-03 | ALKS | Mixed | +4,239 | -$29.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.